Myeloproliferative Neoplasms
23
8
11
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
13.0%
3 terminated out of 23 trials
70.0%
-16.5% vs benchmark
0%
0 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (23)
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Registry of Patients With MPNs in Taiwan
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders